Abstracts tagged "giant cell arteritis"

Abstract Number: 2399 • ACR Convergence 2023
Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis
Anne Bull Haaversen¹, Tanaz Kermani², Lene Kristin Brekke³, Oyvind Molberg⁴ and Andreas Diamantopoulos⁵, ¹Martina Hansens Hospital, Hosle, Norway, ²Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ³Haugesund Hospoital For Rheumatic Diseases, Haugesund, Nepal, ⁴Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ⁵Akershus University Hospital, Lørenskog, Norway
Background/Purpose: Patients with Giant cell arteritis (GCA) face an elevated risk of aneurysm formation. Despite this, consensus regarding optimal aortic visualization methods and aneurysm monitoring…
Abstract Number: 2415 • ACR Convergence 2023
Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study
Artem Minalyan¹, Christopher Hino¹, Emily He¹, Osahon Idolor², Chinenye Osuorji³, Nneka Chukwu⁴, Ehizogie Edigin¹ and Vaneet Sandhu⁵, ¹Loma Linda University Health, Loma Linda, CA, ²Piedmont Athens Regional Hospital, Atlanta, GA, ³Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁴Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁵Loma Linda University, Loma Linda, CA
Background/Purpose: Giant Cell Arteritis (GCA) is a known risk factor for Aortic Aneurysm/Dissection (AAD). However, it is unclear if patients with GCA have worse hospital…
Abstract Number: 2602 • ACR Convergence 2023
Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis
Cecilia Ansalone¹, Sam McAllister², Ethan Pickerill³, Lin Zhang³, Annie Peacock², Dominic McGovern⁴, Holly Leslie⁵, Victoria Kellior², Evelyn Qian², David Gemperline³, Aysin Tulunay Virlan², Sylvia Wright⁶, Paul Cauchi⁶, Timothy Beckman⁶, Lisa Hutton⁶, John Cole¹, Isabella Wulur³, Robert Benschop³, Nigel Jamieson⁵, Carl Goodyear¹ and Neil Basu¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Glasgow - School of Medicine, Glasgow, United Kingdom, ⁵University of Glasgow - School of Cancer Sciences, Glasgow, United Kingdom, ⁶NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
Background/Purpose: Corticosteroids (CS) remain the mainstay of giant cell arteritis (GCA) therapy. Between ~30-70% patients relapse following CS taper and are consequently at risk of…
Abstract Number: 0766 • ACR Convergence 2023
The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis
Valentin Sebastian Schäfer¹, Tobias Schremmer², Florian Recker³, Wolfgang Hartung⁴, Christina Duftner⁵, Sara Monti⁶, Alojzija Hocevar⁷, Rositsa Karalilova⁸, Annamaria Iagnocco⁹, PIERLUIGI MACCHIONI¹⁰, Giuseppe Antonio Germano¹¹, Maria Esperanza Naredo Sanchez¹², Eugenio De Miguel¹³, Luca Seitz¹⁴, Thomas Daikeler¹⁵, Markus Aschwanden¹⁶, Dennis Boumans¹⁷, Chetan Mukhtyar¹⁸, smith kate¹⁹, Richard Wakefield²⁰, Andreas Diamantopoulos²¹, Stavros Chrysidis²², Berit Dalsgaard Nielsen²³, Kresten Keller²⁴, Uffe Dohn²⁵, Lene Terslev²⁶, Marcin Milchert²⁷, Aaron Juche²⁸, Wolfgang Schmidt²⁹, George A. W. Bruyn³⁰ and Christian Dejaco³¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²Universitätsklinikum Bonn, Bonn, Germany, ³Department for Gynecology and Obstetrics, University Hospital Bonn, Bonn, Germany, ⁴Asklepios Clinic, Tegernheim, Germany, ⁵Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁶Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁷Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, ⁹University of Turin, Roma, Italy, ¹⁰Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ¹¹Rheumatology Unit- Arcispedale Santa Maria Nuova Reggio Emilia-Italy, Reggio Emilia, Italy, ¹²Rheumatology Department and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ¹⁵Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ¹⁶Department of Angiology, University Hospital Basel, Basel, Switzerland, ¹⁷Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, ¹⁸Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹⁹NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²⁰s Leeds Insitute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²¹Akershus University Hospital, Lørenskog, Norway, ²²Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, ²³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, ²⁴Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²⁵Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, ²⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²⁷Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²⁹Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ³⁰Reumakliniek Lelystad, Loenga, Netherlands, ³¹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Ultrasonography has been validated as a diagnostic tool for giant cell arteritis (GCA). There is a need to develop training resources, because the glucocorticoid…
Abstract Number: 1882 • ACR Convergence 2023
Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations
Philipp Bosch¹, Milena Bond², Christian Dejaco³, Cristina Ponte⁴, Sarah Mackie⁵, Louise Falzon⁶, Wolfgang Schmidt⁷ and Sofia Ramiro⁸, ¹Medical University of Graz, Graz, Austria, ²Azienda sanitaria dell'Alto Adige, Merano, Italy, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Sheffield, Sheffield, United Kingdom, ⁷Immanuel Krankenhaus Berlin, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in…
Abstract Number: 2400 • ACR Convergence 2023
Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept
Jean-Paul Makhzoum¹, Stephanie Ducharme-Benard², Samer Hussein², Rosalie-Selene Meunier², Carolyn Ross³, Alik Chamlian⁴, Jonathan Ducharme⁵, Leia Chamlian⁴, Alae Dhahbi⁴, Christian Pagnoux⁶ and Remi Goupil⁷, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Canadian Network for Research on Vasculitides, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Laval University, Montreal, QC, Canada, ⁵University of Sherbrooke, Montreal, QC, Canada, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Hopital du Sacre-Coeur de Montreal, University of Montreal, Montreal, QC, Canada
Background/Purpose: Applanation tonometry (ATn) is a non-invasive, point-of-care tool used to capture arterial pressure waveforms. It can measure arterial pulse wave velocity (PWV), a marker…
Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴, Grainne Murphy⁵ and David Kane⁶, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Cork University Hospital, Cork, Ireland, ⁶Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Christopher Redmond¹, Robert Zorc², McKella Sylvester³, Cameron Rankin⁴, Rebecca Kuan⁵, Kristina Wells⁶, Lily Dai⁷, Kaitlin Quinn⁸, Massimo Gadina⁹ and Peter Grayson¹⁰, ¹National Institutes of Health, Hagerstown, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, ³Colgate University, Bethesda, MD, ⁴NIAMS, NIH, Washington, DC, ⁵NIH, Bethesda, MD, ⁶University of California Davis, Bethesda, MD, ⁷NIH, Germantown, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
Abstract Number: 0800 • ACR Convergence 2023
CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Jose Morales², Yuki Sato², Chenyao Wang², Matthew Koster³, Kenneth Warrington³, Gerald J. Berry⁴, Jorg Goronzy³ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: In Giant Cell Arteritis (GCA), granulomatous infiltrates occupy the vessel wall and elicit maladaptive vascular remodeling with intimal hyperplasia. The major cell types of…
Abstract Number: 1889 • ACR Convergence 2023
Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis
HUGO AVALOS BOGADO¹, GUSTAVO AÑEZ STURCHIO², Ernesto Trallero-Araguas³, Esther Espartal López⁴, sebastián Sandoval Moreno¹, daniela Ulloa Navas⁵ and Juan José De Agustín De Oro², ¹Rheumatology Department Vall d'Hebrón University Hospital, Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁴Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ⁵Rheumatology Department, Vall Hebron University Hospital, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most prevalent type of primary systemic vasculitis among individuals aged 50 and above. Imaging techniques such as ultrasound…
Abstract Number: 2401 • ACR Convergence 2023
A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis
Colm Kirby¹, Sharon Cowley², Rachael Flood¹, Ronan Mullan¹, Grainne Murphy³ and David Kane⁴, ¹Tallaght University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Cork University Hospital, Cork, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) incorporating Axillary Artery US (AAUS) has become a reliable alternative to biopsy for diagnosing GCA but studies…
Abstract Number: 2419 • ACR Convergence 2023
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Elisa Fernandez-Fernandez⁴, Maria. T Silva-Diaz⁵, Joaquín M. Belzunegui⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galíndez¹⁰, javier Mendizábal¹¹, Leticia Leon Mateos¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Iván Castellvi¹⁵, Marina Tortosa-Cabañas¹⁶, Vanesa Navarro¹⁷, Carlos Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Maria Vanesa Hernandez Hernandez²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸ and Ricardo Blanco²⁹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²IDISSC Hospital Clinico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Ramon y Cajal University Hospital, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Visual loss is one of the most feared complications in giant cell arteritis (GCA). Some factors have been previously associated with visual loss, as…
Abstract Number: 1040 • ACR Convergence 2023
Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT
Juan Molina-Collada¹, Isabel Castrejon², Irene Monjo³, Elisa Fernandez-Fernandez⁴, Gabriela Torres⁵, JULIA MARTINEZ BARRIO⁶, Jose María Alvaro-Gracias⁷ and Eugenio De Miguel⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Aortitis is a serious potential complication of patients with giant cell arteritis (GCA) and may lead to dilation, aneurysms or dissection. Since ultrasound (US)…
Abstract Number: 2085 • ACR Convergence 2023
A Survey on Giant Cell Arteritis-Related Knowledge Among Internal Medicine Residents
Helina Maharjan¹, Muhammad Abdullah², Summia Matin Afridi³, Alsayed Osman⁴, Aleena Sammar⁵ and Ahmad Raja⁶, ¹Bassett Medical Center, Cooperstown, NY, ²Islamic International Medical College, Rawalpindi, Pakistan, ³Albany Medical Center, Albany, NY, ⁴AdventHealth Florida, Orlando, FL, ⁵Parkview Medical Center, Pueblo, CO, ⁶Mary Imogene Bassett Hospital, Evanston, IL
Background/Purpose: Giant Cell Arteritis (GCA) poses challenges in clinical practice, necessitating a deep understanding. Internal medicine residents play a crucial role in patient care and…
Abstract Number: 2402 • ACR Convergence 2023
A Retrospective Analysis of Prevalence of Positive Temporal Artery Biopsies in African American Patients with Giant Cell Arteritis (GCA) in a Large Academic Health Center
Leen Al saleh¹, Haya Haddad², sunita Dia³ and Florina Constantinescu², ¹Medstar Washington Hospital Center, Alexandria, VA, ²Medstar Washington Hospital Center, Washington, DC, ³Spartanburg Regional Healthcare System, Greenville, SC
Background/Purpose: Giant Cell Arteritis (GCA) is a systemic vasculitis reportedly more common in Caucasian older adults. Studies suggest that GCA is very rare in African…

« Previous Page
1
…
4
5
6
7
8
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].